Jiehuang Zheng
Overview
Explore the profile of Jiehuang Zheng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
58
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen Y, Zheng J, Mo L, Chen F, Li R, Wang Y, et al.
Phytomedicine
. 2024 May;
129:155688.
PMID: 38728920
Background: Malignant breast cancer cells trigger the over-activation of osteoclast precursor cells, leading to bone loss and severe pain. Targeted inhibition of osteoclast differentiation has emerged as an important strategy...
2.
Zheng J, He W, Chen Y, Li L, Liang Q, Dai W, et al.
J Adv Res
. 2024 Mar;
69:399-411.
PMID: 38556044
Introduction: Breast cancer-related bone metastasis can lead to skeletal-related events (SREs), which decrease patient quality of life. Inhibition of osteoclastogenesis is a key treatment for SREs; however, the availability of...
3.
Wang Y, Liang Q, Chen F, Zheng J, Chen Y, Chen Z, et al.
Viruses
. 2023 Nov;
15(11).
PMID: 38005826
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. The interplay between innate and adaptive immune responses plays a crucial role...
4.
Yang Q, Zhang Z, Chen Z, Wang Y, Chen Y, Zheng J, et al.
Immunology
. 2023 Sep;
170(4):567-578.
PMID: 37688314
Sepsis is a life-threatening disease characterized by multiple organ dysfunction. B cells play a pivotal role in sepsis. Here, we first observed the significantly reduced Flot2 gene expression in B...
5.
Yang Q, Guo J, Zheng J, Chen Y, Zou B, Li R, et al.
Int Immunopharmacol
. 2023 May;
120:110316.
PMID: 37253315
Bone is a preferred metastatic site of advanced breast cancer and the 5-year overall survival rate of breast cancer patients with bone metastasis is only 22.8%. Targeted inhibition of osteoclasts...
6.
Tan Y, Ke M, Li Z, Chen Y, Zheng J, Wang Y, et al.
Front Pharmacol
. 2022 Feb;
12:753240.
PMID: 35111044
It is a viable strategy to inhibit osteoclast differentiation for the treatment of osteolytic diseases such as osteoporosis, rheumatoid arthritis and tumor bone metastases. Here we assessed the effects of...
7.
Deng W, Ding Z, Wang Y, Zou B, Zheng J, Tan Y, et al.
Phytomedicine
. 2021 Nov;
96:153838.
PMID: 34801352
Background: Osteolytic diseases share symptoms such as bone loss, fracture and pain, which are caused by over-activated osteoclasts. Targeting osteoclast differentiation has emerged as a therapeutic strategy clinically. Dendrobine is...
8.
Zou B, Zheng J, Deng W, Tan Y, Jie L, Qu Y, et al.
Phytomedicine
. 2020 Oct;
80:153377.
PMID: 33126167
Background: Osteoporosis is a threat to aged people who have excessive osteoclast activation and bone resorption, subsequently causing fracture and even disability. Inhibiting osteoclast differentiation and absorptive functions has become...
9.
Liao P, He Y, Yang F, Luo G, Zhuang J, Zhai Z, et al.
Arthritis Res Ther
. 2018 Nov;
20(1):254.
PMID: 30419963
Background: Neutrophil extracellular trap (NET) formation has been described to be closely involved in the pathogenesis of systemic lupus erythematosus (SLE). In this study, we aimed to investigate the effect...